Advertisement
ILMN vs TMO
Which Stock Would AI Choose? Illumina (ILMN) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- ILMN has delivered stronger relative performance over the past year, with returns around 79% compared to TMO's 21%, driven by genomics momentum.
- TMO boasts a larger market capitalization of approximately $174 billion versus ILMN's $19.5 billion, reflecting greater diversification.
- Recent weeks show TMO facing pressure post-Q1 earnings despite revenue growth, while ILMN benefits from partnerships and product updates.
- Year-to-date, TMO leads with about 19% gains compared to ILMN's 2%, highlighting stability in broader life sciences.
- Both stocks trade at comparable forward P/E ratios around 24-26, but ILMN offers higher growth potential in genomics.
Introduction
Illumina (ILMN) and Thermo Fisher Scientific (TMO) are key players in the life sciences sector, with ILMN specializing in genomic sequencing and TMO providing diversified tools and services. This stock comparison analyzes their recent market positioning, performance drivers, and relative strengths amid evolving biotech demands. Traders seeking momentum opportunities and investors focused on sector stability will find insights into business models, sentiment shifts, and growth catalysts, aiding informed decisions in the current market environment.
ILMN Overview and Recent Performance
Illumina, Inc. (ILMN) develops sequencing- and array-based solutions for genetic analysis, serving research institutions, biotech firms, and diagnostics labs globally. Its core offerings include next-generation sequencing (NGS) instruments, consumables, and software like DRAGEN for multiomic workflows. In recent market activity, ILMN shares have stabilized around $128, rebounding significantly from 52-week lows near $74 amid a 62% one-year gain. Positive sentiment stems from expanded partnerships, such as with Labcorp for precision oncology NGS and the Center for Data-Driven Discovery in Biomedicine for pediatric cancer research, alongside software enhancements supporting new assays. Upcoming earnings are anticipated to reflect core revenue growth, bolstering confidence in genomics demand.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) delivers comprehensive life sciences solutions across four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It supports drug development, research, and manufacturing with instruments, consumables, and services. Recent weeks have seen TMO shares trade near $468 after a post-earnings dip, despite Q1 revenue rising 6% to $11 billion; organic growth concerns and a revised outlook pressured the stock from 52-week highs above $640. Key developments include a $1.08 billion sale of its microbiology business to Astorg, aiming to streamline operations amid biopharma strength.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of 25 top-performing AI trading bots from over 350 available on the platform, which collectively trade thousands of tickers across diverse strategies. These bots, categorized as Signal Agents, Virtual Agents, and Brokerage Agents, adapt to current market conditions like volatility (low to high) using technical and fundamental analysis. Operating on timeframes from 5-minute to 60-minute charts, they offer real-time signals with copy trading options, risk management, and customizable portfolios for various styles—from short-term scalping to longer swings. This elite group represents the most suitable performers, helping traders navigate dynamic environments efficiently. Explore Tickeron’s Trending AI Robots to identify bots aligning with your strategy.
Head-to-Head Comparison
ILMN focuses on high-growth genomics sequencing, capitalizing on rising demand for personalized medicine and research, while TMO’s diversified model spans instruments, diagnostics, and biopharma services for steadier revenue streams. Growth drivers differ: ILMN benefits from NGS adoption and partnerships, versus TMO’s bioprocessing tailwinds offset by macro headwinds. Recent momentum favors ILMN’s rebound, contrasting TMO’s earnings volatility. Risk factors include ILMN’s narrower exposure to sequencing cycles versus TMO’s scale mitigating downturns. Sector-wise, both tap life sciences, but market sentiment tilts toward ILMN for innovation upside amid TMO’s stability trade-off.
Tickeron AI Verdict
Tickeron’s AI models currently favor ILMN over TMO in the near term, citing superior trend consistency from its multi-month rebound, fresh catalysts like partnerships, and relative outperformance. While TMO offers defensive positioning, ILMN’s genomics momentum provides probabilistic edge in volatile biotech markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ILMN is a Hold and TMO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ILMN’s FA Score shows that 3 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- ILMN’s FA Score: 3 green, 2 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ILMN’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- ILMN’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
ILMN (@Medical Specialties) experienced а -0.62% price change this week, while TMO (@Medical Specialties) price change was +3.50% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.03%. For the same industry, the average monthly price growth was +9.32%, and the average quarterly price growth was +10.59%.
Reported Earning Dates
ILMN is expected to report earnings on Aug 12, 2026.
TMO is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical Specialties (+3.03% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ILMN | TMO | ILMN / TMO | |
| Capitalization | 28.5B | 195B | 15% |
| EBITDA | 1.43B | 11.7B | 12% |
| Gain YTD | 34.607 | -9.486 | -365% |
| P/E Ratio | 29.34 | 25.51 | 115% |
| Revenue | 4.39B | 45.2B | 10% |
| Total Cash | 1.16B | 1.12B | 103% |
| Total Debt | 2.54B | 43.2B | 6% |
ILMN | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 79 | |
SMR RATING 1..100 | 30 | 62 | |
PRICE GROWTH RATING 1..100 | 7 | 51 | |
P/E GROWTH RATING 1..100 | 7 | 43 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is somewhat better than the same rating for ILMN (75) in the Biotechnology industry. This means that TMO’s stock grew somewhat faster than ILMN’s over the last 12 months.
TMO's Profit vs Risk Rating (79) in the Medical Specialties industry is in the same range as ILMN (100) in the Biotechnology industry. This means that TMO’s stock grew similarly to ILMN’s over the last 12 months.
ILMN's SMR Rating (30) in the Biotechnology industry is in the same range as TMO (62) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to TMO’s over the last 12 months.
ILMN's Price Growth Rating (7) in the Biotechnology industry is somewhat better than the same rating for TMO (51) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than TMO’s over the last 12 months.
ILMN's P/E Growth Rating (7) in the Biotechnology industry is somewhat better than the same rating for TMO (43) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than TMO’s over the last 12 months.
| ILMN | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 64% | 1 day ago 59% |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 73% | 1 day ago 61% |
| Advances ODDS (%) | 8 days ago 70% | 1 day ago 62% |
| Declines ODDS (%) | 16 days ago 79% | 3 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 60% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 60% |
Advertisement
ILMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with BRKR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then BRKR could also see price increases.
| Ticker / NAME | Correlation To ILMN | 1D Price Change % | ||
|---|---|---|---|---|
| ILMN | 100% | N/A | ||
| BRKR - ILMN | 60% Loosely correlated | N/A | ||
| RVTY - ILMN | 58% Loosely correlated | +0.82% | ||
| AZTA - ILMN | 51% Loosely correlated | N/A | ||
| TMO - ILMN | 50% Loosely correlated | +1.97% | ||
| A - ILMN | 50% Loosely correlated | -2.02% | ||
More | ||||